ClinicalTrials.gg
CompletedNCT04270760Updated Mar 31, 2026Results posted

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

A Phase 2 interventional study of Olpasiran and Placebo in Cardiovascular Disease, sponsored by Amgen. Completed at 36 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Olpasiran
  • AMG 890
  • siRNA
  • lipoprotein (a) Lp(a)
  • Cardiovascular
  • Cardiovascular disease
  • Atherosclerotic cardiovascular disease
  • Cholesterol
  • Apolipoprotein (B)
  • Hyperlipidemia
  • Dyslipidemia
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 281 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years
  • Lipoprotein (a) > 150 nmol/L
  • Evidence of atherosclerotic cardiovascular disease

Exclusion criteria

Exclusion Criteria:

  • Severe renal dysfunction
  • History or clinical evidence of hepatic dysfunction
  • within the last 5 years
  • Currently receiving, or less than 3 months at Day 1 since receiving > 200 mg/day Niacin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
281 participants (actual)

Study arms

  • Active comparator
    Arm 1 Olpasiran Dose 1

    Drug: Olpasiran

  • Active comparator
    Arm 2 Olpasiran Dose 2

    Drug: Olpasiran

  • Active comparator
    Arm 3 Olpasiran Dose 3

    Drug: Olpasiran

  • Active comparator
    Arm 4 Olpasiran Dose 4

    Drug: Olpasiran

  • Placebo comparator
    Arm 5 Placebo Dose 5

    Drug: Placebo

Interventions

  • Dose 1 Dose 2 Dose 3 Dose 4

    Also known as: AMG 890

  • DrugPlacebo

    Dose 5

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

    Time frame: Baseline and Week 36

Secondary outcomes

  1. Percentage Change From Baseline in Lp(a) at Week 48

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

    Time frame: Baseline and Week 48

  2. Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 36 and Week 48

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

    Time frame: Baseline; Week 36 and Week 48

  3. Percentage Change From Baseline in Apolipoprotein (B) (ApoB) at Week 36 and Week 48

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

    Time frame: Baseline; Week 36 and Week 48

  4. Mean Serum Olpasiran Concentrations at Day 1, Week 24 and Week 48

    Pharmacokinetic blood draws were collected at one timepoint during the 6-12 and 24-72 hour flexible time windows and at Week 48. Lower limit of quantification (LLOQ) = 0.400 ng/mL. Values below the LLOQ were set to zero.

    Time frame: Pre-dose and 1, 3, 6-12, and 24-72 hours post-dose on Day 1 and Week 24; Week 48

07

Results

Posted Aug 23, 2023

Participant flow

This study was conducted at 34 centers in Australia, Denmark, Iceland, the Netherlands, Canada, the United States, and Japan between 28 July 2020 and 08 November 2022.

Participant flow — Overall Study
MilestoneGroup 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12W
Started5858565554
Entered extended safety follow-up period5757545553
Completed5755525553
Not completed13401
Withdrew: Withdrawal by subject01300
Withdrew: Lost to follow-up12100
Withdrew: Death00001

Outcome measures

PrimaryPercentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

Time frame:
Baseline and Week 36
Reported as:
Least squares mean · Percentage Change in Lp(a)
Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36
Percentage Change in Lp(a)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12W
Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36-66.91 ± 1.78-93.78 ± 1.78-97.53 ± 1.82-96.89 ± 1.853.60 ± 1.89
Statistical analysis
  • Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 (Adjusted p-value is reported based on the Hochberg procedure to control the type I error for multiple comparisons. Each individual adjusted p-value is compared to 0.05 to determine statistical significance.) · Treatment difference: -70.51 · 95% CI -75.12 to -65.90Treatment difference = percentage change in Group 1 - percentage change in Group 5 from Baseline at Week 36.
  • Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 (Adjusted p-value is reported based on the Hochberg procedure to control the type I error for multiple comparisons. Each individual adjusted p-value is compared to 0.05 to determine statistical significance.) · Treatment difference: -97.38 · 95% CI -101.98 to -92.77Treatment difference = percentage change in Group 2 - percentage change in Group 5 from Baseline at Week 36.
  • Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 (Adjusted p-value is reported based on the Hochberg procedure to control the type I error for multiple comparisons. Each individual adjusted p-value is compared to 0.05 to determine statistical significance.) · Treatment difference: -101.13 · 95% CI -105.79 to -96.47Treatment difference = percentage change in Group 3 - percentage change in Group 5 from Baseline at Week 36.
  • Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = < 0.001 · Treatment difference: -100.49 · 95% CI -105.16 to -95.82Treatment difference = percentage change in Group 4 - percentage change in Group 5 from Baseline at Week 36.
SecondaryPercentage Change From Baseline in Lp(a) at Week 48

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · Percentage Change in Lp(a)
Percentage Change From Baseline in Lp(a) at Week 48
Percentage Change in Lp(a)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12W
Percentage Change From Baseline in Lp(a) at Week 48-64.89 ± 2.17-92.54 ± 2.17-97.29 ± 2.22-82.36 ± 2.253.59 ± 2.30
Statistical analysis
  • Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -68.47 · 95% CI -74.27 to -62.67Treatment difference = percentage change in Group 1 - percentage change in Group 5 from Baseline at Week 48.
  • Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -96.12 · 95% CI -101.92 to -90.33Treatment difference = percentage change in Group 2 - percentage change in Group 5 from Baseline at Week 48.
  • Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -100.88 · 95% CI -106.74 to -95.02Treatment difference = percentage change in Group 3 - percentage change in Group 5 from Baseline at Week 48.
  • Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = < 0.001 · Treatment difference: -85.94 · 95% CI -91.83 to -80.06Treatment difference = percentage change in Group 4 - percentage change in Group 5 from Baseline at Week 48.
SecondaryPercentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 36 and Week 48

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

Time frame:
Baseline; Week 36 and Week 48
Reported as:
Least squares mean · Percentage Change in LDL-C
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 36 and Week 48
Percentage Change in LDL-CGroup 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12W
Week 36-17.425 ± 4.258-16.284 ± 4.259-16.733 ± 4.389-18.462 ± 4.4286.234 ± 4.520
Week 48-14.743 ± 4.419-11.481 ± 4.418-17.308 ± 4.532-16.908 ± 4.60810.113 ± 4.688
Statistical analysis
  • Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -23.659 · 95% CI -35.176 to -12.143Treatment difference = percentage change in Group 1 - percentage change in Group 5 from Baseline at Week 36.
  • Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -22.518 · 95% CI -34.036 to -11.000Treatment difference = percentage change in Group 2 - percentage change in Group 5 from Baseline at Week 36.
  • Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -22.967 · 95% CI -34.656 to -11.278Treatment difference = percentage change in Group 3 - percentage change in Group 5 from Baseline at Week 36.
  • Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = < 0.001 · Treatment difference: -24.696 · 95% CI -36.399 to -12.993Treatment difference = percentage change in Group 4 - percentage change in Group 5 from Baseline at Week 36.
  • Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -24.856 · 95% CI -36.853 to -12.859Treatment difference = percentage change in Group 1 - percentage change in Group 5 from Baseline at Week 48.
  • Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -21.594 · 95% CI -33.590 to -9.598Treatment difference = percentage change in Group 2 - percentage change in Group 5 from Baseline at Week 48.
  • Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -27.421 · 95% CI -39.565 to -15.277Treatment difference = percentage change in Group 3 - percentage change in Group 5 from Baseline at Week 48.
  • Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -27.021 · 95% CI -39.240 to -14.801Treatment difference = percentage change in Group 4 - percentage change in Group 5 from Baseline at Week 48.
SecondaryPercentage Change From Baseline in Apolipoprotein (B) (ApoB) at Week 36 and Week 48

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

Time frame:
Baseline; Week 36 and Week 48
Reported as:
Least squares mean · Percentage Change in ApoB
Percentage Change From Baseline in Apolipoprotein (B) (ApoB) at Week 36 and Week 48
Percentage Change in ApoBGroup 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12W
Week 36-11.496 ± 2.886-9.302 ± 2.885-10.241 ± 2.960-11.378 ± 3.0127.394 ± 3.066
Week 48-7.748 ± 3.307-4.768 ± 3.305-7.218 ± 3.393-9.548 ± 3.44312.292 ± 3.501
Statistical analysis
  • Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -18.890 · 95% CI -26.303 to -11.477Treatment difference = percentage change in Group 1 - percentage change in Group 5 from Baseline at Week 36.
  • Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -16.696 · 95% CI -24.107 to -9.284Treatment difference = percentage change in Group 2 - percentage change in Group 5 from Baseline at Week 36.
  • Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -17.635 · 95% CI -25.139 to -10.131Treatment difference = percentage change in Group 3 - percentage change in Group 5 from Baseline at Week 36.
  • Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = < 0.001 · Treatment difference: -18.772 · 95% CI -26.303 to -11.241Treatment difference = percentage change in Group 4 - percentage change in Group 5 from Baseline at Week 36.
  • Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -20.040 · 95% CI -28.757 to -11.323Treatment difference = percentage change in Group 1 - percentage change in Group 5 from Baseline at Week 48.
  • Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -17.060 · 95% CI -25.774 to -8.345Treatment difference = percentage change in Group 2 - percentage change in Group 5 from Baseline at Week 48.
  • Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -19.509 · 95% CI -28.336 to -10.682Treatment difference = percentage change in Group 3 - percentage change in Group 5 from Baseline at Week 48.
  • Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W · Repeated measures linear effects model · p = <0.001 · Treatment difference: -21.839 · 95% CI -30.700 to -12.979Treatment difference = percentage change in Group 4 - percentage change in Group 5 from Baseline at Week 48.
SecondaryMean Serum Olpasiran Concentrations at Day 1, Week 24 and Week 48

Pharmacokinetic blood draws were collected at one timepoint during the 6-12 and 24-72 hour flexible time windows and at Week 48. Lower limit of quantification (LLOQ) = 0.400 ng/mL. Values below the LLOQ were set to zero.

Time frame:
Pre-dose and 1, 3, 6-12, and 24-72 hours post-dose on Day 1 and Week 24; Week 48
Reported as:
Mean · ng/mL
Mean Serum Olpasiran Concentrations at Day 1, Week 24 and Week 48
ng/mLGroup 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24W
Day 1: Pre-dose0.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00
Day 1: 1 Hour Post-dose12.3 ± 6.967.1 ± 47.4220 ± 218275 ± 450
Day 1: 3 Hours Post-dose18 ± 9.8580.3 ± 43.2291 ± 273324 ± 383
Day 1: 6-12 Hours Post-dose18.6 ± 10.161.7 ± 36420 ± 432329 ± 191
Day 1: 24-72 Hours Post-dose0.995 ± 0.94620.4 ± 13.263.2 ± 59.7103 ± 47.3
Week 24: Pre-dose0.00 ± 0.000.0315 ± 0.1340.498 ± 1.880.0645 ± 0.22
Week 24: 1 Hour Post-dose12.4 ± 7.2373.6 ± 43.6204 ± 144253 ± 247
Week 24: 3 Hours Post-dose16.3 ± 9.296.3 ± 63.5278 ± 193332 ± 255
Week 24: 6-12 Hours Post-dose17.2 ± 10.276.3 ± 54.7271 ± 229315 ± 191
Week 24: 24-72 Hours Post-dose1.27 ± 1.8217.3 ± 18.999 ± 59.196.3 ± 50.3
Week 480.00 ± 0.000.0599 ± 0.1680.533 ± 0.5920.127 ± 0.693

Adverse events

Collected over Treatment Period: Median duration was 11.07 months. Extended Safety Follow-up Period: Median duration was 8.56 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1; Treatment Period: Olpasiran 10 mg Q12W0/58 (0%)3/58 (5.2%)35/58 (60.3%)
Group 2; Treatment Period: Olpasiran 75 mg Q12W0/58 (0%)3/58 (5.2%)40/58 (69%)
Group 3; Treatment Period: Olpasiran 225 mg Q12W0/56 (0%)6/56 (10.7%)37/56 (66.1%)
Group 4; Treatment Period: Olpasiran 225 mg Q24W0/55 (0%)4/55 (7.3%)36/55 (65.5%)
Group 5; Treatment Period: Placebo Q12W1/54 (1.9%)8/54 (14.8%)29/54 (53.7%)
Group 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12W0/57 (0%)4/57 (7%)18/57 (31.6%)
Group 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12W0/57 (0%)2/57 (3.5%)25/57 (43.9%)
Group 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12W0/54 (0%)6/54 (11.1%)21/54 (38.9%)
Group 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24W0/55 (0%)5/55 (9.1%)17/55 (30.9%)
Group 5; Extended Safety Follow-up: Placebo Q12W0/53 (0%)4/53 (7.5%)17/53 (32.1%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventGroup 1; Treatment Period: Olpasiran 10 mg Q12WGroup 2; Treatment Period: Olpasiran 75 mg Q12WGroup 3; Treatment Period: Olpasiran 225 mg Q12WGroup 4; Treatment Period: Olpasiran 225 mg Q24WGroup 5; Treatment Period: Placebo Q12WGroup 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12WGroup 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12WGroup 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12WGroup 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24WGroup 5; Extended Safety Follow-up: Placebo Q12W
OsteoarthritisMusculoskeletal and connective tissue disorders0/580/581/560/550/540/570/572/540/550/53
CholangitisHepatobiliary disorders0/580/580/560/550/540/570/570/540/551/53
Cervical spinal stenosisMusculoskeletal and connective tissue disorders0/580/580/560/550/540/570/570/540/551/53
Gastrointestinal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/580/580/560/550/540/570/570/540/551/53
Metastases to pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/580/580/560/550/540/570/570/540/551/53
Ischaemic strokeNervous system disorders0/580/580/560/550/540/570/570/540/551/53
Angina pectorisCardiac disorders0/580/580/560/551/541/570/570/540/550/53
Angina unstableCardiac disorders1/580/581/560/551/540/570/570/540/550/53
Rectal haemorrhageGastrointestinal disorders0/580/580/560/550/540/570/571/540/550/53
Non-cardiac chest painGeneral disorders0/580/580/560/551/540/570/570/540/550/53
Most frequent other events
Showing 10 of 32
Most frequent other events
EventGroup 1; Treatment Period: Olpasiran 10 mg Q12WGroup 2; Treatment Period: Olpasiran 75 mg Q12WGroup 3; Treatment Period: Olpasiran 225 mg Q12WGroup 4; Treatment Period: Olpasiran 225 mg Q24WGroup 5; Treatment Period: Placebo Q12WGroup 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12WGroup 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12WGroup 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12WGroup 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24WGroup 5; Extended Safety Follow-up: Placebo Q12W
COVID-19Infections and infestations1/588/587/564/556/548/5711/5714/5410/5510/53
FatigueGeneral disorders6/588/583/562/553/542/571/570/540/551/53
Immunisation reactionImmune system disorders8/584/582/564/555/540/570/572/540/550/53
Back painMusculoskeletal and connective tissue disorders6/585/587/561/553/543/571/571/541/550/53
HeadacheNervous system disorders6/587/586/566/554/540/571/572/541/550/53
Injection site painGeneral disorders2/583/581/565/552/540/570/570/540/550/53
Injection site bruisingGeneral disorders0/584/585/560/554/540/570/570/540/550/53
DiarrhoeaGastrointestinal disorders2/583/583/561/554/540/570/570/541/550/53
MyalgiaMusculoskeletal and connective tissue disorders3/581/584/564/554/542/570/570/540/550/53
Injection site erythemaGeneral disorders0/583/583/564/550/540/570/570/540/550/53

Baseline characteristics

Full Analysis Set (FAS): includes all randomized participants who received at least one dose of IP.

Age, Continuous
Age, Continuous(Years)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12WTotal
Mean63.4 ± 9.561.3 ± 9.259.7 ± 10.161.8 ± 9.463.4 ± 8.961.9 ± 9.5
Age, Customized
Age, Customized(Participants)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12WTotal
18 - 64 years3135373129163
65 - 74 years191718191790
75 - 84 years8615828
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12WTotal
Female122315221890
Male4635413336191
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12WTotal
Hispanic or Latino200226
Not Hispanic or Latino5658565352275
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Olpasiran 10 mg Q12WGroup 2: Olpasiran 75 mg Q12WGroup 3: Olpasiran 225 mg Q12WGroup 4: Olpasiran 225 mg Q24WGroup 5: Placebo Q12WTotal
Asian6555324
Black or African American012126
White5252474948248
Other002013
08

Study locations

36 sites
  • Westside Medical Associates of Los Angeles
    Beverly Hills, California 90211, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Piedmont Healthcare
    Atlanta, Georgia 30309, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • New York University
    New York, New York 10016, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Crossroads Clinical Research Inc
    Mooresville, North Carolina 28117, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Protenium Clinical Research
    Hurst, Texas 76054, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Core Research Group Pty Ltd
    Milton, Queensland 4064, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Linear Clinical Research Limited
    Nedlands, Western Australia 6009, Australia
  • Dr Heart Pty Ltd
    Woolloongabba, 4102, Australia
  • LMC Clinical Research Incorporated
    Brampton, Ontario L6S 0C6, Canada
  • LMC Clinical Research Incorporated Thornhill
    Concord, Ontario L4K 4M2, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Institute of McGill University Health Center - Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Clinique des Maladies Lipidiques de Quebec Incorporated
    Québec, Quebec G1V 4W2, Canada
  • Aarhus Universitetshospital
    Aarhus N, 8200, Denmark
  • Herlev Gentofte Hospital
    Herlev, 2730, Denmark
  • Regionshospitalet Viborg
    Viborg, 8800, Denmark
  • Thjonustumidstod Rannsoknaverkefna
    Kopavogur, 201, Iceland
  • Asahi General Hospital
    Asahi-shi, Chiba 289-2511, Japan
  • The Jikei University Kashiwa Hospital
    Kashiwa-shi, Chiba 277-8567, Japan
  • Asahikawa City Hospital
    Asahikawa-shi, Hokkaido 070-8610, Japan
  • Kanazawa Medical University Hospital
    Kahoku-gun, Ishikawa-ken 920-0293, Japan
  • Saitama Medical University Hospital
    Iruma-gun, Saitama 350-0495, Japan
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Rijnstate Ziekenhuis
    Arnhem, 6815 AD, Netherlands
  • Haga Ziekenhuis
    The Hague, 2545 AA, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • VieCuri Medisch Centrum
    Venlo, 5912 BL, Netherlands
09

References and documents

Publications

  • O'Donoghue ML, G Lopez JA, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022 Sep;251:61-69. doi: 10.1016/j.ahj.2022.05.004. Epub 2022 May 16. PubMed 35588897 ↗
  • O'Donoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. PubMed 36342163 ↗
  • O'Donoghue ML, Rosenson RS, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Murphy SA, Wang H, Wu Y, Shah T, Wang J, Wilmanski T, Sohn W, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results. J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058. PubMed 39168564 ↗
  • Kaur G, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Park JG, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study. Eur Heart J. 2025 Mar 24;46(12):1162-1164. doi: 10.1093/eurheartj/ehae781. No abstract available. PubMed 39565305 ↗
  • Rosenson RS, Lopez JAG, Gaudet D, Baum SJ, Stout E, Lepor NE, Park JG, Murphy SA, Knusel B, Wang J, Wilmanski T, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML; OCEAN(a)-DOSE Trial Investigators. Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial. JAMA Cardiol. 2025 May 1;10(5):482-486. doi: 10.1001/jamacardio.2024.5433. PubMed 39937508 ↗
  • Zimerman A, Lopez JAG, Rosenson RS, Gaudet D, Baum SJ, Park JG, Wang J, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Small-Interfering RNA Olpasiran and Apolipoprotein B Particles. JAMA Cardiol. 2025 Dec 1;10(12):1322-1324. doi: 10.1001/jamacardio.2025.4105. PubMed 41191372 ↗
  • Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiol Rev. 2025 Jul-Aug 01;33(4):352-358. doi: 10.1097/CRD.0000000000000667. Epub 2024 Feb 28. PubMed 38415744 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2021, 16 months.

Results were first posted in Aug 2023, 1 year 7 months after primary completion. A results delay was requested in Oct 2022.

Of 84 phase 2 interventional studies under Cardiovascular Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's 16 months is below that.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Feb 17, 2020
StartActual
Jul 28, 2020
Primary completionActual
Dec 27, 2021
CompletionActual
Nov 8, 2022
Results delay requested
Oct 20, 2022
Results first posted
Aug 23, 2023
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04270760
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Jul 28, 2020
Primary completion
Dec 27, 2021
Completion
Nov 8, 2022
Results posted
Aug 23, 2023
Last update
Mar 31, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olpasiran

Start the discussion